Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).
Lyndsey Runaas, MD
Advertisement
Articles by Lyndsey Runaas, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
4
Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer
5